Chattaraj Bornika, Nandi Arijit, Das Anwesha, Sharma Amit, Dey Yadu Nandan, Kumar Dharmendra, R Mogana
Department of Pharmacology, Dr. B.C. Roy College of Pharmacy and Allied Health Sciences, Durgapur, India.
Department of Pharmacy, Indira Gandhi National Tribal University, Lalpur, India.
Front Pharmacol. 2023 Jan 20;13:982419. doi: 10.3389/fphar.2022.982419. eCollection 2022.
The decoction of the whole plant of is used ethno medicinally by various tribes for the treatment of kidney stones and urinary problems. However, no scientific studies were carried out to delineate its influence on urinary stone formation and crystallisation. Hence, the present study is proposed to investigate the effect of the aqueous extract of extract on crystallisation of calcium oxalate. The present study also evaluated. studies of the metabolites with the target proteins present in the renal calcium oxalate stone matrix. The plant material was subjected to decoction to obtain an aqueous extract. The effect of the extract on calcium oxalate crystallization was evaluated by nucleation and aggregation assays. Further, the metabolites present in were mined from the existing literature and their number was found to be 35. The selected 35 metabolites of were subjected to molecular docking with the 5 proteins which are known to be responsible for calcium oxalate crystal growth. Results of studies indicated that the extract (50, 100, and 200 μg/mL) and standard drug cystone (1,000 μg/mL) exhibited an inhibitory role in the nucleation process where the percentage inhibitions were 52.69, 43.47, 21.98, and 31.67 μg/mL respectively. The results of molecular docking studies revealed that 2 out of 35 metabolites i.e. Baicalein-7-O-diglucoside and 4',5,6,7-Tetrahydroxy-8-methoxy isoflavone-7-O-beta-D- galactopyranosyl-(1→3)-O-beta-D-xylopyranosyl-(1→4)- O-alpha-L-rhamnopyranoside showed modulatory effects on the four renal stone matrix-associated protein (Human CTP: Phosphoethanolamine Cytidylyltransferase (Protein Data Bank ID: 3ELB), UDP glucose: glycoprotein glucosyltransferase 2 (Gene: UGGT2) (AlphaFold) and RIMS-binding protein 3A (Gene: RIMBP3) (AlphaFold), and Ras GTPase activating-like protein (PDB: 3FAY) based on their docking scores which indicates that they may inhibit the crystallization process. Findings from this study show that may be effective in the prevention of the crystallization of calcium oxalate. However, further, studies as well as molecular studies are needed to be conducted to confirm and strengthen its anti-urolithiatic activity and to elucidate the possible mechanism of action involved therein.
该植物全草煎剂被不同部落用于民族医学中治疗肾结石和泌尿系统问题。然而,尚未进行科学研究来阐明其对尿路结石形成和结晶的影响。因此,本研究旨在探讨该植物提取物水提物对草酸钙结晶的影响。本研究还评估了该植物代谢产物与肾草酸钙结石基质中存在的靶蛋白的相互作用。将植物材料进行煎煮以获得水提物。通过成核和聚集试验评估提取物对草酸钙结晶的影响。此外,从现有文献中挖掘该植物中存在的代谢产物,发现其数量为35种。将所选的35种该植物代谢产物与已知负责草酸钙晶体生长的5种蛋白质进行分子对接。研究结果表明,提取物(50、100和200μg/mL)和标准药物胱石通(1000μg/mL)在成核过程中发挥抑制作用,其抑制百分比分别为52.69、43.47、21.98和31.67μg/mL。分子对接研究结果显示,35种代谢产物中的2种,即黄芩苷-7-O-二葡萄糖苷和4',5,6,7-四羟基-8-甲氧基异黄酮-7-O-β-D-吡喃半乳糖基-(1→3)-O-β-D-吡喃木糖基-(1→4)-O-α-L-吡喃鼠李糖苷,基于其对接分数对四种与肾结石基质相关的蛋白质(人CTP:磷酸乙醇胺胞苷转移酶(蛋白质数据库ID:3ELB)、UDP葡萄糖:糖蛋白葡糖基转移酶2(基因:UGGT2)(AlphaFold)和RIMS结合蛋白3A(基因:RIMBP3)(AlphaFold)以及Ras GTP酶激活样蛋白(PDB:3FAY)显示出调节作用,这表明它们可能抑制结晶过程。本研究结果表明该植物可能对预防草酸钙结晶有效。然而,需要进一步进行体内研究以及分子研究来证实并加强其抗尿石症活性,并阐明其中可能涉及的作用机制。